Forbes April 18, 2022
Rita Numerof

Our firm has been measuring progress along the journey to population health for 7 years. That progress has been painfully slow. While the pandemic did shine a light on why we need a predictable revenue model in healthcare delivery focused on prevention and primary care, bailouts and rescues have kept a dying fee-for-service model on continued life support. Population health represents a real opportunity for providers to improve not only the health and well-being of those they serve, but also their own financial health.

However, and despite general agreement with this outlook among industry insiders, our research highlights that most providers have yet to commit themselves to a new model. Instead, the general theme has been to blame others for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma, Pharma / Biotech, Population Health Mgmt
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices

Share This Article